Efficacy of rituximab in refractory antisynthetase syndrome

Internal Medicine Journal

Volumn 42, Issue 3, 2012, Pages

  Limaye, V ^a,b   Hissaria, P ^c   Liew, C L ^a   Koszyka, B ^c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Antisynthetase syndrome; Autoantibody; Jo 1; Myositis; Rituximab; Ro 52

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB;

ADULT; ANTISYNTHETASE SYNDROME; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL LITERATURE; MUSCLE BIOPSY; PRIORITY JOURNAL; TOTAL LUNG CAPACITY; TREATMENT DURATION; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AMINO ACYL-TRNA SYNTHETASES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CERVICAL INTRAEPITHELIAL NEOPLASIA; DERMATOMYOSITIS; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; PARANEOPLASTIC SYNDROMES; REMISSION INDUCTION; SYNDROME; UTERINE CERVICAL NEOPLASMS;

EID: 84858711482     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02702.x     Document Type: Article

References (16)

1. Limaye V, Blumbergs P, Roberts-Thomson PJ. Idiopathic inflammatory myopathies. Intern Med J 2009; 39: 179-90.
2. Hengstman GJD, van Engelena BGM, van Venrooijb WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004; 16: 692-9.
3. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996; 26: 459-67.
4. Schmidt WA, Wetzel W, Friedländer R, Lange R, Sörensen HF, Lichey HJ etal. Clinical and serological aspects of patients with anti-Jo-1 autoantibodies - an evolving spectrum of disease manifestations. Clin Rheumatol 2000; 19: 371-7.
5. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A etal. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-20.
6. Limaye V, Lester S, Bardy P, Thompson P, Cox S, Blumbergs P etal. A three way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. Rheumatol Int 2010; [Epub ahead of print].
7. Rios Fernandez R, Callejas Rubio JL, Sanchez Cano D, Saez Moreno JA, Ortego Centeno N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27: 1009-16.
8. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-7.
9. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of anti-synthetase syndrome. Ann Rheum Dis 2006; 65: 974-5.
10. La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta R. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006; 39: 249-53.
11. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005; 32: 1369-70.
12. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome - a retrospective case series. Rheumatology (Oxford) 2009; 48: 968-71.
13. Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, ter Borg EJ, van cen Bosch JMM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009; 29: 1499-502.
14. Amoura Z, Duhaut P, Huong DL, Wechsler B, Costedoat-Chalumeau N, Francès C etal. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 2005; 14: 1279-82.
15. Szekanecz E, Sándor Z, Antal-Szalmás P, Soós L, Lakos G, Besenyei T etal. Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann N Y Acad Sci 2007; 1108: 359-71.
16. Cantagrel A, Moulinier L, Beljio K, Duffaut M, Laroche M, Bon E etal. Increase of CA 19.9 in dysimmune inflammatory rheumatism. Apropos of 6 cases. Rev Rhum Ed Fr 1994; 61: 599-606.